Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others.

Fizazi K.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e161. Review.

2.

Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.

Dellis A, Papatsoris AG.

Expert Opin Biol Ther. 2014 Jan;14(1):7-10. doi: 10.1517/14712598.2013.840582. Epub 2013 Sep 27.

PMID:
24074253
3.

Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.

Vignani F, Bertaglia V, Buttigliero C, Tucci M, Scagliotti GV, Di Maio M.

Cancer Treat Rev. 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Epub 2016 Feb 12. Review.

PMID:
26907461
4.

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.

Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Epub 2013 Aug 16. Review.

5.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
6.

Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.

Zustovich F, Fabiani F.

Crit Rev Oncol Hematol. 2014 Aug;91(2):197-209. doi: 10.1016/j.critrevonc.2014.01.003. Epub 2014 Jan 17. Review.

PMID:
24503416
7.

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

Picciotto M, Franchina T, Russo A, Ricciardi GRR, Provazza G, Sava S, Baldari S, Caffo O, Adamo V.

Expert Opin Pharmacother. 2017 Jun;18(9):899-908. doi: 10.1080/14656566.2017.1323875. Epub 2017 May 8. Review.

PMID:
28449621
8.

Targeting bone metastases in prostate cancer: improving clinical outcome.

Body JJ, Casimiro S, Costa L.

Nat Rev Urol. 2015 Jun;12(6):340-56. doi: 10.1038/nrurol.2015.90. Epub 2015 May 5. Review.

PMID:
26119830
9.

Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.

Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.

Q J Nucl Med Mol Imaging. 2015 Dec;59(4):400-10. Epub 2015 Sep 3. Review.

PMID:
26337241
10.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-9. doi: 10.1016/j.eururo.2014.06.045. Epub 2014 Jul 10.

PMID:
25018038
11.

Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.

Saad F, Miller K.

Urol Oncol. 2014 Feb;32(2):70-9. doi: 10.1016/j.urolonc.2013.01.005. Epub 2013 Mar 15.

PMID:
23506965
12.

Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.

Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.

Expert Opin Investig Drugs. 2014 Apr;23(4):469-87. doi: 10.1517/13543784.2014.885950. Epub 2014 Feb 3. Review.

PMID:
24490883
14.

[New therapies in metastatic castration resistant prostate cancer].

Thibault C, Massard C.

Bull Cancer. 2015 Jun;102(6):501-8. doi: 10.1016/j.bulcan.2015.04.016. Epub 2015 May 26. Review. French.

PMID:
26022286
15.

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS).

Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037. Epub 2015 Aug 13.

PMID:
26278646
16.

Pathologic fracture in patients with metastatic prostate cancer.

Gartrell BA, Saad F.

Curr Opin Urol. 2014 Nov;24(6):595-600. doi: 10.1097/MOU.0000000000000105. Review.

PMID:
25166424
17.

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.

Quintela ML, Mateos LL, Estévez SV, Calvo OF, Herranz UA, Afonso FJ, Santomé L, Aparicio LA.

Cancer Treat Rev. 2015 Mar;41(3):247-53. doi: 10.1016/j.ctrv.2014.12.006. Epub 2015 Jan 8. Review.

PMID:
25638257
18.

Drug therapies for metastatic castration-resistant prostate cancer.

El-Bahesh E, Finianos A, Alfaraj A, Aragon-Ching JB.

Future Oncol. 2015;11(17):2395-403. doi: 10.2217/fon.15.168. Epub 2015 Aug 14. Review.

PMID:
26274603
19.

New agents for prostate cancer.

Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J.

Ann Oncol. 2014 Sep;25(9):1700-9. doi: 10.1093/annonc/mdu038. Epub 2014 Mar 20. Review.

PMID:
24658665
20.

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.

Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11. Review.

PMID:
23957948

Supplemental Content

Support Center